However, these ICIs targeting PD-L1 and PD1 have a significant disadvantage that more than half of patients do not respond to PD-1/PD-L1 immunotherapy (5), suggesting the presence of other costimulatory signaling pathways in the tumor microenvironment of LUAD. The gene discussed is PDCD1; the disease is neoplasm.